The production of the ACE recombinant antibody begins with the synthesis of the ACE antibody-encoding gene. The process of obtaining the ACE antibody gene involves immunizing animals with a synthesized peptide derived from human ACE, followed by the isolation of B cells and fusion with myeloma cells to generate hybridomas. The resulting hybridomas are screened for ACE antibody production and the gene sequence of the variable light and heavy domains are determined, which is then cloned into a vector. The vector containing the ACE monoclonal antibody gene is then transfected into cells for cultivation, and the resulting ACE recombinant monoclonal antibody is purified through affinity chromatography from the cell culture supernatant. The purified ACE recombinant monoclonal antibody is specifically able to react with only human ACE samples and has been successfully tested in ELISA and IHC applications.
The ACE protein is an important enzyme involved in the regulation of blood pressure and electrolyte balance. In cells, it functions by converting angiotensin I to angiotensin II, which is a potent vasoconstrictor and increases blood pressure. The ACE protein also breaks down bradykinin, a peptide that causes vasodilation and reduces blood pressure, thereby contributing to the regulation of blood pressure. Additionally, the ACE protein is involved in the inactivation of other vasoactive peptides and has been implicated in a variety of physiological processes, such as inflammation, oxidative stress, and cell growth.
